Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis
about
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2Isoniazid metabolism and hepatotoxicityInvolvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control studyMeta-Analysis-Based Preliminary Exploration of the Connection between ATDILI and Schizophrenia by GSTM1/T1 Gene PolymorphismsGenetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced HepatotoxicityInfluence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol)Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.Pharmacogenomics of antimicrobial agents.Pharmacogenetics of isoniazid-induced hepatotoxicity.NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS.HLA-DQ B1*0201 and A1*0102 Alleles Are Not Responsible for Antituberculosis Drug-Induced Hepatotoxicity Risk in Spanish Population.GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis.Future of pharmacogenetics-based therapy for tuberculosis.Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity.Update meta-analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug-induced hepatotoxicity: evidence from 26 studies.Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice.Hepatic and Intra-abdominal Tuberculosis: 2016 Update.Improved genotyping of N-acetyltransferase 2: role of the ultra-slow acetylators.Baseline HBV load increases the risk of anti-tuberculous drug-induced hepatitis flares in patients with tuberculosis.PharmGKB summary: isoniazid pathway, pharmacokinetics.Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study.Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population.Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity.Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives
P2860
Q27011622-960283D1-B8B6-4426-ABEC-B031664EECCAQ28076859-5E56327F-A29A-45BD-917C-9887108DB1BDQ28544822-2C37B26F-DEA4-4076-B045-A1396B0F5861Q28547892-AC940D8A-B6B6-421A-A199-E87655625F40Q28550148-FE066657-7232-49B8-AC8D-0FCF8FD951F2Q33901424-4849812B-F163-4B8E-A021-02E0CFE93C0DQ34342305-AA834200-6BFC-458C-9DE0-9BB88F384C71Q34977413-A1C27D23-D106-4D5B-8E51-77A03C35C03FQ35669887-6F30D8E6-B3FA-4748-8790-62752C02F00EQ35934555-9872E279-29D9-426E-BCD0-5975CC423446Q36058879-25E3A5E9-4C6D-49A0-9987-ED14A70BC460Q37193472-6DA581F4-6748-4E97-95D9-03D123E967ACQ38078780-38FB2E01-5796-4B43-8A8C-5924F1254238Q38209573-3AF684EA-128B-4C0C-BFE4-9AC52517364BQ38360770-BD364E7D-7B77-4788-87D1-BF6B8D6BB058Q38381479-0F000105-3064-4900-9B7C-31737C7BFABEQ38391340-8A12F574-E3E1-4D7D-840E-1B9C2FACBF77Q38994724-21A15F46-BA59-4C74-8E87-07F2A0A32ED4Q39336687-3C5DF8A2-F81C-4BCB-BDB0-EF5A19C8FADFQ40322550-CB70EA01-9FD7-4431-BC96-E62B08AC22FFQ42090708-95D988D3-3C0E-414D-B772-F90B0CC4A9C8Q42335970-8882B481-1670-4AC3-B152-238E639FA81EQ42708451-EA55CF06-B77D-4A03-9ABB-81E0A2CF8BB4Q44075475-323F3C93-4D01-48AA-9B7A-700A1DDCBFA9Q45344839-F6068AD4-C2F2-4A52-880F-3654BCF65B7CQ51569750-1095A068-6731-474B-902A-47E16F476116Q51747019-D9196B2E-4023-4F5A-83F3-278AFC70F0E9Q54203690-05C0BF6C-1EF8-4261-ABDB-DACBF0E3C4D0Q58804131-36952BE7-6F21-4131-886A-6905F73F1DDC
P2860
Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pharmacogenetic study of drug- ...... liver injury: a meta-analysis
@ast
Pharmacogenetic study of drug- ...... liver injury: a meta-analysis
@en
Pharmacogenetic study of drug- ...... liver injury: a meta-analysis
@nl
type
label
Pharmacogenetic study of drug- ...... liver injury: a meta-analysis
@ast
Pharmacogenetic study of drug- ...... liver injury: a meta-analysis
@en
Pharmacogenetic study of drug- ...... liver injury: a meta-analysis
@nl
prefLabel
Pharmacogenetic study of drug- ...... liver injury: a meta-analysis
@ast
Pharmacogenetic study of drug- ...... liver injury: a meta-analysis
@en
Pharmacogenetic study of drug- ...... liver injury: a meta-analysis
@nl
P2093
P2860
P3181
P1433
P1476
Pharmacogenetic study of drug- ...... liver injury: a meta-analysis
@en
P2093
ChaoHui Zhou
JiaYong Yi
XiZhong Shen
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0047769
P407
P577
2012-01-01T00:00:00Z